Success is said to breed success, but for AstraZeneca PLC, recent triumphs for its oncology portfolio are not to be taken for granted. As well as diversifying its pipeline through select deals, such as the just-closed acquisition of TeneoTwo, Inc. to boost its hemato-oncology presence, the company is banking on success with its pipeline of novel anticancers to take its offering to the next level. Oncology R&D chief Susan Galbraith talked to Scrip about some of the more promising earlier candidates coming through the pipeline.
AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.
More from R&D
More from Scrip
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.